本文選題：品牌制藥企業(yè)　切入點(diǎn)：仿制藥企業(yè)　出處：《科技管理研究》2017年11期

【摘要】：產(chǎn)品跳躍有改換形式、添加或移除某些化合物、將單獨(dú)出售的兩種或以上藥物以組合形式重新包裝等形式,常常被視為原研藥企阻擊競(jìng)爭(zhēng)對(duì)手仿制藥企的一種戰(zhàn)略,從而受到反壟斷的審查和規(guī)制。然而,排除那些存在制造隱患、惡意詆毀或創(chuàng)新騙局外,更多的產(chǎn)品跳躍是一種創(chuàng)新活動(dòng),對(duì)其嚴(yán)苛監(jiān)管既有悖市場(chǎng)競(jìng)爭(zhēng)規(guī)則,也很難權(quán)衡利弊得失,從長(zhǎng)遠(yuǎn)角度來看還會(huì)在很大程度上抑制整個(gè)行業(yè)的發(fā)展并最終傳導(dǎo)到消費(fèi)者,降低全社會(huì)福祉。
[Abstract]:Product hopping takes the form of changing, adding or removing certain compounds, repackaging two or more drugs sold separately in combination, and so on, often seen as a strategy for the original pharmaceutical industry to block rival generic drug companies. However, excluding those who create hidden dangers, malicious slander or innovation scam, more product jumping is an innovative activity, and strict supervision of it is contrary to the rules of market competition. It is also difficult to weigh the pros and cons. In the long run, it will greatly restrain the development of the whole industry and ultimately transmit to consumers and reduce the welfare of the whole society.
【作者單位】： 臺(tái)州廣播電視大學(xué);臺(tái)州學(xué)院經(jīng)貿(mào)管理學(xué)院;浙江天訟律師事務(wù)所;
【基金】：國(guó)家社會(huì)科學(xué)基金項(xiàng)目“‘戰(zhàn)略-形象’協(xié)同視角下國(guó)家知識(shí)產(chǎn)權(quán)形象建設(shè)研究(13BGL003)
【分類號(hào)】：D922.294;D971.2;DD912.29
，

本文編號(hào)：1658234